The Medical Letter on Drugs and Therapeutics
Vandetanib (Caprelsa) for Medullary Thyroid Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA recently approved vandetanib [van det´ a nib] (Caprelsa – AstraZeneca) for oral treatment of symptomatic or progressive medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Vandetanib is the first drug approved in the US for medullary thyroid cancer.

MEDULLARY THYROID CANCER (MTC) — Medullary thyroid cancer is rare; it is found in about 4% of all thyroid cancers. Total thyroidectomy is the first-line therapy; various chemotherapy regimens including doxorubicin, dacarbazine and 5-fluorouracil have been tried for nonresectable disease with limited success.1

MECHANISM OF ACTION — Vandetanib is an oral tyrosine kinase inhibitor that inactivates vascular endothelial growth factor receptor (VEGFR)-2, epidermal growth factor receptor (EGFR), and rearrangedduring- transfection (RET) tyrosine kinases, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Vandetanib (Caprelsa) for Medullary Thyroid Cancer
Article code: 1381b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian